MedTrace Logo

Efficacy and Safety of Leningrado Association in the Treatment of Hypertension

NCT03814109 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-07-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Leningrado association on the treatment of hypertension.

Conditions

  • Arterial Hypertension

Interventions

DRUG

LENINGRADO association

1 coated sustained-release tablet, oral, once a day.

DRUG

Indapamide SR 1.5 MG

1 coated sustained-release tablet, oral, once a day.

DRUG

Levamlodipine 2.5/ 5 mg

1 tablet, oral, once a day.

OTHER

Leningrado association Placebo

1 coated sustained-release tablet, oral, once a day.

OTHER

Indapamide SR Placebo

1 coated sustained-release tablet, oral, once a day.

OTHER

Levamlodipine placebo

1 tablet, oral, once a day.

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2023-11-30
Completion
2024-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03814109 on ClinicalTrials.gov